Pfizer Inc. (PFE)
Dopo ore:
| Chiusura precedente | 44,34 |
| Aperto | 44,35 |
| Denaro | 0,00 x 1300 |
| Lettera | 0,00 x 4000 |
| Min-Max giorno | 43,88 - 44,39 |
| Intervallo di 52 settimane | 41,45 - 56,32 |
| Volume | |
| Media Volume | 22.094.326 |
| Capitalizzazione | 247,322B |
| Beta (5 anni mensile) | 0,63 |
| Rapporto PE (ttm) | 8,05 |
| EPS (ttm) | 5,47 |
| Prossima data utili | 01 mag 2023 - 05 mag 2023 |
| Rendimento e dividendo (forward) | 1,64 (3,73%) |
| Data ex dividendo | 26 gen 2023 |
| Stima target 1A | 52,77 |
- CoinDesk
VitaDAO Closes $4.1M Funding Round With Pfizer Ventures for Longevity Research
The decentralized autonomous organization is raising funds for research on technologies that target human aging.
- GlobeNewswire
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under the companies’ existing strategic collaborationLianBio is eligible to receive up to $135 million in potential development and commercial milestone payments and tiered low single digit percent of net sales in the territories SHANGHAI, China
- GlobeNewswire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase 2b study (TUSCANY-2) with final results expected in 1H 2023 BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PF
